The global hospital acquired Infections therapeutic market size is expected to be worth around US$ 13.7 billion by 2030, according to a new report by Vision Research Reports.
The global hospital acquired Infections therapeutic market size was valued at US$ 10.5 billion in 2020 and is anticipated to grow at a CAGR of 2.8% during forecast period 2021 to 2030.
|Drug Class, Infection Type|
|Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Allergan Plc.|
The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.
According to the data published by the New York State Department of Health in November 2019, around 160 hospitals in New York reported total cases of around 1,139 colon SSIs out of 19,732 procedures in 2018, a rate of 5.8 infections per 100 procedures. The same source also states that in 2018, around 15,310 cases of Clostridioides difficile infections (CDI) were reported in acute care hospitals located in New York. Such, high prevalence of hospital-acquired infections is anticipated to significantly raise the demand for its treatment therapies and support the HAIs therapeutics market growth over the forecast period.
the Surgical Site Infections (SSIs) segment dominated the market for HAIs therapeutics and held the largest revenue share of 31.8% due to the rising number of surgical procedures and subsequent rising cases of SSIs. According to CDC, nearly 27 million surgical procedures are performed every year in the U.S., out of which 5% of the patients develop SSIs. SSIs affect as many as 300,000 patients in the U.S. every year. Such types of infections tend to increase the hospitalization by 7 to 10 days and the hospitalization cost by USD 3,000.
The Urinary tract infections (UTIs) segment is anticipated to show the fastest growth rate during the forecast period owing to the growing number of UTI cases and rising awareness among people about the disease condition in less-developed countries. UTIs commonly affect the kidney, bladder, ureters, and urethra. This condition is common among the women population, around 40% of them experience UTI at some time. The most common type is Catheter-associated UTIs (CA-UTIs) as reported by the National Healthcare Safety Network. It accounted for around two-thirds of the UTIs as per CDC 2017 data. In addition, the introduction of novel drugs for UTI is also another factor generating high growth for the segment in the market for HAIs therapeutics.
The antibacterial drugs segment dominated the market for HAIs therapeutics and accounted for the largest revenue share of 87.3% in 2019. This dominance is attributed to the fact that the majority of the HAIs are caused by bacteria. Hence, a large ratio of HAIs is treated with antibacterial drugs.
Furthermore, antibacterial therapy is the first line of treatment for any type of hospital-acquired infection. All patients affected with gram-positive and gram-negative pathogens are required to be treated with antibiotics. Empiric antibiotic therapy should be considered initially on the basis of various risk factors for multidrug-resistant pathogens. Empiric antibiotic therapy is performed to avoid complications such as renal damage, pyelonephritis, and bloodstream infections. Antibacterial therapy might be as short as 7 days or as large as 14-21 days.
Europe dominated the market for HAIs therapeutics and accounted for the largest revenue share of 35.4% in 2019 and is expected to dominate the market throughout the study period. This dominance is attributed to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European countries due to the local presence of major players such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG., Allergan Plc, and Bayer AG is further expected to support regional growth.
In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period. This growth is attributed to the increasing prevalence of chronic diseases in emerging economies such as India and China which has led to increased hospitalizations. For instance, according to the data published by Globocan, in 2018 around 4,285,033 new cases of cancer were diagnosed in China. Thus, the increasing rate of HAIs with increasing hospitalizations is anticipated to foster demand for HAI therapeutic drugs and support regional growth.
Merck & Co., Inc.
Daiichi Sankyo Company, Limited
F. Hoffmann-La Roche Ltd
By Drug Class Outlook
Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
By Infection Type Outlook
Urinary Tract Infections
Surgical Site Infections
Other Hospital Infections
The Hospital Acquired Infections Therapeutic market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Hospital Acquired Infections Therapeutic market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Hospital Acquired Infections Therapeutic market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hospital Acquired Infections Therapeutic market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Hospital Acquired Infections Therapeutic market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Hospital Acquired Infections Therapeutic capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Hospital Acquired Infections Therapeutic by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Hospital Acquired Infections Therapeutic market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Hospital Acquired Infections Therapeutic market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Hospital Acquired Infections Therapeutic market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Hospital Acquired Infections Therapeutic industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Hospital Acquired Infections Therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Hospital Acquired Infections Therapeutic market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Hospital Acquired Infections Therapeutic market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Hospital Acquired Infections Therapeutic market. These factors have benefited the growth of the global market for Hospital Acquired Infections Therapeutic. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Hospital Acquired Infections Therapeutic. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Hospital Acquired Infections Therapeutic are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are: